Zydus Lifesciences in Talks to Acquire Ardelyx, Stock Rises
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 20 Jan 26
Source: seekingalpha
Ardelyx Inc's stock price increased by 15.11% as it reached a 5-day high amid discussions of an acquisition by Zydus Lifesciences.
The rise in Ardelyx's stock is attributed to Zydus Lifesciences being in talks to acquire the company, which has led to strong market optimism regarding the potential deal. This acquisition could provide Ardelyx with additional funding support for future growth, especially given its projected product revenue of approximately $378 million in 2025.
The implications of this acquisition could significantly enhance Ardelyx's market position and attract further investor interest, despite the overall market decline reflected in the Nasdaq-100 and S&P 500.
Analyst Views on ARDX
Wall Street analysts forecast ARDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARDX is 14.33 USD with a low forecast of 10.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.850
Low
10.00
Averages
14.33
High
19.00
Current: 7.850
Low
10.00
Averages
14.33
High
19.00
About ARDX
Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing first-in-class medicines. The Company has two commercial products approved in the United States: IBSRELA (tenapanor) and XPHOZAH (tenapanor). IBSRELA is a first-in-class NHE3 inhibitor approved by the United States FDA for the treatment of irritable bowel syndrome with constipation in adults. XPHOZAH is a first-in-class phosphate absorption inhibitor approved in the United States to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. It has agreements for the development and commercialization of tenapanor outside of the United States. Kyowa Kirin commercializes PHOZEVEL (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
